Opus Genetics, Inc. (IRD) NASDAQ
4.66
-0.14(-2.92%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.66
-0.14(-2.92%)
Currency In USD
| Previous Close | 4.8 |
| Open | 4.68 |
| Day High | 4.79 |
| Day Low | 4.6 |
| 52-Week High | 5.3 |
| 52-Week Low | 0.65 |
| Volume | 922,949 |
| Average Volume | 918,018 |
| Market Cap | 325.71M |
| PE | -5.82 |
| EPS | -0.8 |
| Moving Average 50 Days | 3.32 |
| Moving Average 200 Days | 2 |
| Change | -0.14 |
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
GlobeNewswire Inc.
Mar 10, 2026 11:00 AM GMT
- Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of FDA’s Rare Pediatric Disease Priority Review Voucher (
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in p
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
GlobeNewswire Inc.
Feb 27, 2026 3:10 PM GMT
Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and thre